Folate metabolism (interference)

Folate metabolism interference" is not a specific molecular target but rather describes a **therapeutic strategy** that involves inhibiting one or more enzymes in the folic acid metabolic pathway. This pathway is essential for the synthesis of nucleotides required for DNA and RNA production as well as methylation reactions critical for cell function. Drugs that interfere with this pathway—collectively known as antifolates—are used primarily in cancer chemotherapy and antimicrobial therapy because they preferentially affect rapidly dividing cells by blocking key steps in nucleotide biosynthesis. The most common molecular targets within this strategy are **dihydrofolate reductase** (DHFR) and **thymidylate synthase** (TYMS), among others. While effective against malignant or microbial cells, these drugs also pose significant toxicity risks to normal proliferating tissues. "Folate metabolism interference" should not be considered a canonical drug target itself; instead, it refers to a class effect involving multiple specific enzyme targets within the broader folic acid metabolic network.[1][2][3][4]

Other names

Folate pathway inhibitionAntifolate targetFolic acid metabolism interferenceInhibition of folic acid cycle enzymes

Inhibition of dihydrofolate reductase (DHFR); Inhibition of thymidylate synthase (TYMS); Inhibition of other folate-dependent enzymes such as serine hydroxymethylmethyltransferase and glycinamide-ribonucleotide transformylase